Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.

Veronese, L; Rautaureau, J; Sadler, B M; Gillotin, C; Petite, J P; Pillegand, B; Delvaux, M; Masliah, C; Fosse, S; Lou, Y; Stein, D S

Veronese, L; Rautaureau, J; Sadler, B M; Gillotin, C; Petite, J P; Pillegand, B; Delvaux, M; Masliah, C; Fosse, S; Lou, Y; Stein, D S.

Affiliation

Veronese L; Laboratoire Glaxo Wellcome, 78163 Marly-le-Roi, France. lv48262@glaxowellcome.co.uk

Antimicrob Agents Chemother ; 44(4): 821-6, 2000 Apr.

Article in En | MEDLINE | ID: mdl-10722476

Subject(s)

HIV Protease Inhibitors/pharmacokinetics; HIV-1/enzymology; Liver Diseases/metabolism; Sulfonamides/pharmacokinetics; Adult; Area Under Curve; Carbamates; Female; Furans; HIV Protease Inhibitors/adverse effects; HIV Protease Inhibitors/blood; Humans; Liver Cirrhosis/metabolism; Male; Middle Aged; Protein Binding; Sulfonamides/adverse effects; Sulfonamides/blood

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / HIV-1 / HIV Protease Inhibitors / Liver Diseases Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Antimicrob Agents Chemother Year: 2000 Document type: Article Affiliation country: France Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google